68 related articles for article (PubMed ID: 21514794)
21. Treatment adherence and insight in schizophrenia.
Bitter I; Fehér L; Tényi T; Czobor P
Psychiatr Hung; 2015; 30(1):18-26. PubMed ID: 25867885
[TBL] [Abstract][Full Text] [Related]
22. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review.
Valenstein M; Ganoczy D; McCarthy JF; Myra Kim H; Lee TA; Blow FC
J Clin Psychiatry; 2006 Oct; 67(10):1542-50. PubMed ID: 17107245
[TBL] [Abstract][Full Text] [Related]
23. Relapse and long-acting injectable risperidone: a 1-year mirror image study with a national claims database in Taiwan.
Su KP; Chang HC; Tsai SJ; Yen FC; Tang CH
Value Health; 2009; 12 Suppl 3():S118-21. PubMed ID: 20586973
[TBL] [Abstract][Full Text] [Related]
24. Long-acting risperidone and oral antipsychotics in unstable schizophrenia.
Rosenheck RA; Krystal JH; Lew R; Barnett PG; Fiore L; Valley D; Thwin SS; Vertrees JE; Liang MH;
N Engl J Med; 2011 Mar; 364(9):842-51. PubMed ID: 21366475
[TBL] [Abstract][Full Text] [Related]
25. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia.
Offord S; Lin J; Mirski D; Wong B
Adv Ther; 2013 Mar; 30(3):286-97. PubMed ID: 23483449
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data.
Rajagopalan K; Hassan M; O'Day K; Meyer K; Grossman F
J Med Econ; 2013 Jul; 16(7):951-61. PubMed ID: 23701260
[TBL] [Abstract][Full Text] [Related]
27. Association between second-generation antipsychotic medication half-life and hospitalization in the community treatment of adult schizophrenia.
Broder MS; Bates JA; Jing Y; Hebden T; Forbes RA; Chang E
J Med Econ; 2012; 15(1):105-11. PubMed ID: 21991926
[TBL] [Abstract][Full Text] [Related]
28. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
[TBL] [Abstract][Full Text] [Related]
29. Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone.
Leal A; Rosillon D; Mehnert A; Jarema M; Remington G
Pharmacoepidemiol Drug Saf; 2004 Nov; 13(11):811-6. PubMed ID: 15386706
[TBL] [Abstract][Full Text] [Related]
30. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia.
Gilmer TP; Dolder CR; Lacro JP; Folsom DP; Lindamer L; Garcia P; Jeste DV
Am J Psychiatry; 2004 Apr; 161(4):692-9. PubMed ID: 15056516
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness analysis of pharmacological treatments in schizophrenia: critical review of results and methodological issues.
Basu A
Schizophr Res; 2004 Dec; 71(2-3):445-62. PubMed ID: 15474916
[TBL] [Abstract][Full Text] [Related]
32. Insight: demographic differences and associations with one-year outcome in schizophrenia and schizoaffective disorder.
Wiffen BD; Rabinowitz J; Fleischhacker WW; David AS
Clin Schizophr Relat Psychoses; 2010 Oct; 4(3):169-75. PubMed ID: 20880827
[TBL] [Abstract][Full Text] [Related]
33. A cost-consequence analysis of long-acting injectable risperidone in schizophrenia: a one-year mirror-image study with national claim-based database in Taiwan.
Chang HC; Tang CH; Huang ST; McCrone P; Su KP
J Psychiatr Res; 2012 Jun; 46(6):751-6. PubMed ID: 22440883
[TBL] [Abstract][Full Text] [Related]
34. Costs of schizophrenia during 5 years.
Lindström E; Eberhard J; Neovius M; Levander S
Acta Psychiatr Scand Suppl; 2007; (435):33-40. PubMed ID: 17953524
[TBL] [Abstract][Full Text] [Related]
35. How representative of everyday clinical populations are schizophrenia patients enrolled in clinical trials?
Riedel M; Strassnig M; Müller N; Zwack P; Möller HJ
Eur Arch Psychiatry Clin Neurosci; 2005 Apr; 255(2):143-8. PubMed ID: 15549345
[TBL] [Abstract][Full Text] [Related]
36. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission.
Valenstein M; Copeland LA; Blow FC; McCarthy JF; Zeber JE; Gillon L; Bingham CR; Stavenger T
Med Care; 2002 Aug; 40(8):630-9. PubMed ID: 12187177
[TBL] [Abstract][Full Text] [Related]
37. Veteran subjects willingness to participate in schizophrenia clinical trials.
Hoblyn JC; Rosenheck RA; Leatherman S; Weil L; Lew R;
Psychiatr Q; 2013 Jun; 84(2):209-18. PubMed ID: 23143523
[TBL] [Abstract][Full Text] [Related]
38. The Business Case for Expanded Clozapine Utilization.
Gören JL; Rose AJ; Smith EG; Ney JP
Psychiatr Serv; 2016 Nov; 67(11):1197-1205. PubMed ID: 27301766
[TBL] [Abstract][Full Text] [Related]
39. Guideline implementation and patient-tailoring strategies to improve medication adherence for schizophrenia.
Hudson TJ; Owen RR; Thrush CR; Armitage TL; Thapa P
J Clin Psychiatry; 2008 Jan; 69(1):74-80. PubMed ID: 18312040
[TBL] [Abstract][Full Text] [Related]
40. The cost of relapse and the predictors of relapse in the treatment of schizophrenia.
Ascher-Svanum H; Zhu B; Faries DE; Salkever D; Slade EP; Peng X; Conley RR
BMC Psychiatry; 2010 Jan; 10():2. PubMed ID: 20059765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
